Guodong Chen
About Guodong Chen
Guodong Chen is the Scientific Director of Analytical Development & Attribute Sciences at Bristol Myers Squibb, with over 20 years of experience in the pharmaceutical industry.
Scientific Director at Bristol Myers Squibb
Guodong Chen is a Scientific Director in the Analytical Development & Attribute Sciences division at Bristol Myers Squibb in New Jersey. In his role, he focuses on developing methodologies and strategies for characterizing drug targets and therapeutic modalities. His extensive experience in the pharmaceutical industry contributes to advancing candidate molecules from discovery through to development.
Senior Principal Scientist at Schering-Plough Research Institute
From 1999 to 2009, Guodong Chen served as a Senior Principal Scientist at Schering-Plough Research Institute in New Jersey. During his decade-long tenure, he gained significant experience in analytical development and contributed to numerous scientific projects aimed at drug discovery and development.
Ph.D. in Analytical Chemistry from Purdue University
Guodong Chen received his Ph.D. in Analytical Chemistry from Purdue University. This academic background has been foundational in his career, providing him with specialized knowledge and expertise that he has applied extensively in the pharmaceutical industry.
Extensive Experience in Pharmaceutical Industry
With over 20 years of experience in the pharmaceutical industry, Guodong Chen has developed and implemented innovative platform technologies and methodologies for characterization and assay development. His comprehensive background enables him to lead program strategies and matrix teams effectively, facilitating the transition of candidate molecules from discovery phases to development stages.
Prolific Author and Inventor
Guodong Chen has authored or co-authored over 95 publications in peer-reviewed journals and book chapters, demonstrating his active contribution to scientific knowledge. Additionally, he has served as the editor or co-editor for three books focused on pharmaceutical and biopharmaceutical analysis. As a co-inventor, he holds more than 30 U.S. patents, both issued and pending.